• ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 LIVE!™
Insights
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA accepting 2023 grant applications for animal drugs for minor uses and minor species

June 7, 2022

Pharmaceutical sponsors who meet the eligibility requirements or their research partners are encouraged to apply.

The FDA has opened a new period for applications for grants to support the development and potential approval or conditional approval of new animal drugs intended to treat uncommon diseases (minor uses) in major species—horses, dogs, cats, cattle, pigs, turkeys, and chickens—or to treat minor species (MUMS drugs).1

The maximum individual award amount is $250,000 per year per awardee, for up to 2 years for routine studies and up to 3 years for toxicology studies, for a total of $500,000 and $750,000, respectively. Only animal drug sponsors with designated MUMS animal drugs or their research partners are eligible to apply.1

The grant program funds studies on clinical effectiveness, target animal safety (TAS), human food safety, and environmental safety, as well as certain manufacturing studies that are supportive of effectiveness or TAS, according to the FDA.2

Pharmaceutical sponsors developing MUMS drugs must have opened an Investigational New Animal Drug file with the FDA’s Center for Veterinary Medicine (CVM) to meet eligibility requirements for the grant program, and they must already hold a MUMS designation for that drug and its intended use. Additionally, the CVM’s Office of New Animal Drug Evaluation must have reviewed and accepted the study protocol for the pharmaceutical sponsor to be eligible.2

Research partners are required to submit a letter to the INAD file that identifies the partnership with their pharmaceutical sponsors to be eligible for the grant program.2

To date, the MUMS grant program has provided more than $5.86 million in support of 64 studies. In January 2022, the FDA awarded a new grant to AQUI-S New Zealand, Ltd. for $250,000, for an oral 2-generation reproductive toxicity study of eugenol in rats. This study is intended to support the human food safety technical section needed for approval of eugenol to sedate freshwater finfish to handleable condition.1

The Minor Use and Minor Species Animal Health Act of 2004 (the MUMS Act) helps provide innovative ways to bring products to market for these small populations and is designed to help veterinary pharmaceutical companies and others overcome the financial roadblocks they face in providing animal drugs for a limited market. Before this legislation, veterinary pharmaceutical companies and others would rarely attempt to bring such drugs to market.1

Grants awarded through the MUMS program support the FDA’s continuing mission to assure that safe and effective animal drugs are available for a wide range of species and conditions. MUMS grants have been awarded to support product development for a variety of indications, including the treatment and control of specific parasitic and bacterial diseases in various fish species, the treatment of certain cancers in dogs, and some uses for horses, pheasants, and goats.1

The due date to submit an optional Letter of Intent to apply for a grant is June 13, 2022, and applications must be submitted by July 29, 2022, through www.grants.gov or the NIH ASSIST system. The complete NOFO is available at https://grants.nih.gov/grants/guide/pa-files/PAR-21-179.html.1

References

  1. FDA opens first FY2023 grant funding application period for animal drugs for minor uses and minor species. News release. FDA Center for Veterinary Medicine. May 31. 2022. Accessed June 4, 2022. https://www.fda.gov/animal-veterinary/cvm-updates/fda-opens-first-fy2023-grant-funding-application-period-animal-drugs-minor-uses-and-minor-species
  2. FDA Center for Veterinary Medicine. Minor Use/Minor Species (MUMS) Grants. FDA. Accessed June 4, 2022. https://www.fda.gov/media/89240/download

Related Content:

FDAPharmacy
FDA grants conditional approval for drug delaying start of congestive heart failure in canines
FDA grants conditional approval for drug delaying start of congestive heart failure in canines
New antibiotic for cattle and swine is available
New antibiotic for cattle and swine is available
ACANA hairball control food receives FDA approval
ACANA hairball control food receives FDA approval

Latest News

A pet pig patient requires these items to be stocked for proper care

Rare Przewalski's horse foal born at an England zoo

3 Must-reads from DIVM

Shepherd Veterinary Software debuts new pet portal

View More Latest News